Manulife Financial is one of the Big Three Canadian life insurers... Show more
Manulife Financial Corporation (MFC) has traded with a moderately positive tilt in recent weeks, reflecting a stable macroeconomic backdrop, constructive equity markets, and continued progress on reducing its legacy insurance exposure. As of late October 2026, the stock sat near $44.63 on the New York Stock Exchange, up roughly 5% over the prior month and maintaining a market capitalization above $70 billion. The name has also delivered a strong year-to-date advance, supported by consistent earnings delivery and active capital returns.
Within the life and health insurance sector, Manulife is followed closely by investors for its diversified geographic footprint and its shift toward fee-based, capital-light earnings. A forward price-to-earnings multiple in the low teens keeps the valuation within a range that many market participants view as reasonable relative to peers.
Headquartered in Toronto, Manulife is one of the world's largest international financial services providers. The company operates as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States, offering insurance, financial advice, and health solutions to individuals, groups, and businesses. At the end of 2025, it employed more than 37,000 people and served over 37 million customers across 25 markets.
The business is organized around two core pillars. Global Wealth & Asset Management, branded as Manulife Investment Management, provides investment solutions, retirement plan services, and advice to retail, institutional, and retirement clients. The insurance and annuity segment spans Asia, Canada, and the U.S., covering individual life insurance, group benefits, long-term care, and annuity products. A central strategic priority has been growing fee-based and protection earnings, particularly in high-growth Asian markets such as Hong Kong, mainland China, Japan, and Singapore, while reducing capital-intensive legacy risk.
Several verified developments have shaped investor sentiment toward Manulife over the trailing 30 days. The most significant was the completion of a long-term care reinsurance transaction with Munich Re Life US, announced in August and closed on October 1, 2026. The deal transfers biometric risk on a block of U.S. long-term care policies with roughly C$3.2 billion of reserves under an 80% quota share, materially lowering the volatility of a historically challenging line of business.
The company also reported second-quarter 2026 results that exceeded consensus expectations, posting core earnings growth and double-digit growth in new insurance business, with Asia contributing meaningfully. Leadership updates included the appointment of a new Chief Actuary. On the analyst front, RBC Capital and National Bank reiterated Buy ratings, while Barclays maintained a Hold and Scotiabank downgraded the stock to Sector Perform, citing a broadly constructive outlook for Canadian lifecos but limited near-term upside. Manulife also continued its capital-return program through dividends and share repurchases.
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies from a much larger universe of AI-driven bots. Tickeron offers hundreds of AI trading robots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section, giving traders a focused view of strategies gaining traction in current market conditions. These bots vary widely in their approach, timeframe, and performance metrics, ranging from short-term pattern recognition to longer-horizon trend following. The page is designed to help users quickly identify strategies aligned with their own trading style and risk tolerance. Exploring the section can offer a practical starting point for those interested in algorithmic approaches to markets.
Looking ahead, the most immediate catalyst for Manulife is its third-quarter 2026 earnings release, scheduled for after market close on November 4, 2026, followed by a management conference call the next morning. Investors will be watching for sustained core earnings growth, the pace of new business in Asia, and the trajectory of net flows in Global Wealth & Asset Management.
Beyond earnings, key themes include the company's medium-term goal of lifting core return on equity, further de-risking of legacy long-term care exposure through reinsurance, and ongoing capital returns through dividends and buybacks. Macroeconomic factors — including interest-rate levels, equity market performance, and currency movements across Canadian, U.S., and Asian operations — will continue to influence results, as will regulatory developments and competitive dynamics in Asian insurance and global asset management. These factors, rather than any single data point, are likely to define the stock's direction through the remainder of 2026.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MFC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 23 of 32 cases where MFC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 72%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
MFC moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MFC crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +2.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where MFC advanced for three days, in 223 of 349 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 191 of 355 cases where MFC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
The 10-day RSI Indicator for MFC moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 23 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 51%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MFC as a result. In 39 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 51%.
The Moving Average Convergence Divergence Histogram (MACD) for MFC turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 21 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 46%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MFC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. MFC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.537) is normal, around the industry mean (1.337). P/E Ratio (11.686) is within average values for comparable stocks, (19.773). Projected Growth (PEG Ratio) (0.876) is also within normal values, averaging (0.463). Dividend Yield (0.033) settles around the average of (0.047) among similar stocks. P/S Ratio (1.780) is also within normal values, averaging (1.303).
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of life and health insurance and reinsurance services
Industry LifeHealthInsurance